Find a Doctor Employment at WakeMed Events & Education For Physicians For Employees Contact Us

Health Care Encyclopedia

Health Information Encyclopedia - Disease & Conditions

Superficial anterior muscles
Superficial anterior muscles

Guillain-Barre syndrome

Definition:

Guillain-Barre syndrome is a�serious disorder that�occurs when the body's defense (immune) system mistakenly attacks part of the nervous system. This leads to nerve inflammation that causes muscle weakness, which continues to get worse.



Alternative Names: Landry-Guillain-Barre syndrome; Acute idiopathic polyneuritis; Infectious polyneuritis; Acute inflammatory polyneuropathy

Causes, incidence, and risk factors:

Guillain-Barre syndrome is an autoimmune disorder. The exact cause of Guillain-Barre syndrome is unknown. The syndrome�may occur at any age, but is most common in people of both sexes between the ages 30 and 50. It often follows a minor infection, usually a respiratory (lung) infection or gastrointestinal (gut) infection. Usually, signs of the original infection have disappeared before the symptoms of Guillain-Barre begin.

Guillain-Barre syndrome causes�inflammation that damages parts of�nerves. This nerve damage causes tingling, muscle weakness, and paralysis. The inflammation usually affects the nerve's covering (myelin sheath). Such damage is called demyelination. Demyelination slows nerve signaling. Damage�to other parts of the nerve can cause the nerve to stop working.

Guillain-Barre syndrome may occur along with viral infections�such as:

It may also occur with other medical conditions such as systemic lupus erythematosus or Hodgkin's disease.

Some people may get Guillain-Barre syndrome after a bacterial infection, certain vaccinations (such as rabies and swine flu), and surgery.



Symptoms:

Symptoms of Guillain-Barre get worse very quickly.�It may take only a few hours to�reach the most severe symptoms.

Muscle weakness or the loss of muscle function (paralysis) affects both sides of the body.��If the�muscle�weakness starts in the legs and then spreads to the arms, it is called ascending paralysis.

Patients may notice tingling, foot or hand pain, and clumsiness. As the loss of muscle function gets�worse, the patient may need breathing assistance.

Typical symptoms include:

  • Muscle weakness or loss of muscle function (paralysis)
    • Weakness begins in the feet and legs and may�move up to the arms and head
    • May get worse over 24 to 72 hours
    • May�start in the arms and move�downward
    • May�begin in the arms and legs at the same time
    • May�occur in the nerves of the head only
    • In mild cases, weakness or paralysis may not occur
  • Uncoordinated movement
  • Sensation changes
  • Numbness, decreased sensation
  • Tenderness or muscle pain (may be a cramp-like pain)

Additional symptoms may include:

  • Blurred vision
  • Difficulty moving face muscles
  • Clumsiness and falling
  • Palpitations (sensation of feeling heartbeat)
  • Muscle contractions

Emergency symptoms (seek immediate medical help):



Signs and tests:

A history of increasing muscle weakness and paralysis may indicate Guillain-Barre syndrome, especially if there was a recent illness.

A medical exam may show�muscle weakness and problems with involuntary (autonomic) body functions such as blood pressure and heart rate.

There may be signs of decreased breathing�(caused by paralysis of the breathing muscles), and a decrease in certain arm and leg reflexes.

The following tests may be ordered:

  • NCV (nerve conduction velocity) shows nerve damage.
  • EMG��tests the electrical activity in muscles. It may�shows that nerves do not react�properly to stimulation.�
  • CSF (cerebrospinal fluid) may have increased levels of�protein without an increase in white blood cells.
  • ECG may show heart problems in some cases.


Treatment:

There is no cure for Guillain-Barre syndrome. However, many treatments are available to help reduce symptoms, treat complications, and speed up recovery.

When symptoms are severe,�the patient will need to�go to the hospital for breathing help, treatment, and physical therapy.

A method called plasmaphoresis is used to remove a person's blood and replace it with intravenous (IV) fluids or donated blood that is free of proteins called antibodies.

High-dose immunoglobulin therapy (IVIg)�is another procedure used to reduce the severity and length of Guillain-Barre symptoms.

Other treatments are directed at preventing complications.�

  • Proper body positioning or a feeding tube may be used to prevent�choking during feeding.�
  • Blood thinners may be used to prevent blood clots.
  • Pain is treated aggressively with anti-inflammatory medicines and narcotics, if needed.


Support Groups:

Guillain-Barre Syndrome Foundation International - www.gbsfi.com



Expectations (prognosis):

Recovery can take weeks or years. Most people survive and recover completely. According to the National Institute of Neurological Disorders and Stroke, about 30 percent of patients still have some weakness after 3 years. Mild weakness may persist for some people.

A patient's�outcome is most likely to be very good when the�symptoms go away within 3 weeks after they�first started (onset).



Complications:
  • Breathing difficulty (respiratory failure)
  • Sucking in�food or fluids into the lungs (aspiration)
  • Pneumonia
  • Increased risk of infections
  • Deep vein thrombosis
  • Permanent loss of movement of an area
  • Contractures of joints or other deformity


Calling your health care provider:

Seek immediate medical help if any of the following symptoms occur:

  • Loss of movement
  • Decreased feeling (sensation)
  • Difficulty swallowing
  • Difficulty breathing
  • Unable to take a deep breath
  • Fainting


Prevention:



References:

Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002063. Review.

Sharar E. Current therapeutic options in severe Guillain-Barre syndrome. Clin Neuropharmacol. 2006 Jan-Feb;29(1):45-51.

Wiles CM, Brown P, Chapel H, et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):440-8. Review.

Goetz, CG. Textbook of Clinical Neurology. 2nd ed. St. Louis, Mo: WB Saunders;�2003: 1085-1090.




Review Date: 4/28/2006
Reviewed By: Daniel Kantor, M.D., Director of the Comprehensive MS Center, Neuroscience Institute, University of Florida Health Science Center, Jacksonville, FL. Review provided by VeriMed Healthcare Network.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 2002 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

adam.com

Heart Center
Women's Pavilion & Birthplace
Children's Center
Center for Patient Safety
Emergency Services/Trauma
Rehab


To read our disclaimer, click here